Pfizer Is Staking Its Turnaround on Cancer Drugs
Wall Street Journal
Chris Boshoff, top oncology executive, counts on gains from the $43 billion Seagen merger.
Understanding current events through the lenses of the past and future.
Wall Street Journal
Chris Boshoff, top oncology executive, counts on gains from the $43 billion Seagen merger.